ReviewOpen medicine (Warsaw, Poland)2025
C-reactive protein-to-albumin ratio in peripheral artery disease.
Review in Open medicine (Warsaw, Poland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: The aim of this study was to assess the prognostic performance of the C-reactive protein-to-albumin ratio (CAR) in predicting mortality and amputation of peripheral artery disease (PAD) patients undergoing endovascular therapy (EVT). Methods: We conducted a systematic search from the inception date to June 12, 2025, in eight databases and a manual search to cover gray literature. High and low CAR were defined according to the optimal cut-off from each study. Meta-analysis was performed to pool prognostic performance. Result: A total of 1,451 subjects from five observational studies were included. The prevalence of mortality and amputation was 4.7 and 21.4%, respectively. Pre-procedural high CAR was associated with a higher risk of mortality (risk ratio [RR] 3.11; 95% confidence interval [CI] 1.22-8.18; Conclusion: CAR was a potential prognostic biomarker to predict mortality and amputation in PAD patients undergoing EVT.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.